Alteron is an early-stage pharmaceutical company focused on the research and development of first-in-class TDP-43 inhibitors, with disease modification potential for cystic fibrosis and neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), as well as Alzheimer's disease (AD).
Chengliang Zhang, Ph.D. Dr. Chengliang Zhang cofounded Alteron Therapeutic Inc. in 2021, where he oversees the day-to-day operation of the business. Prior, Dr. Zhang founded Alteron Therapeutic LLC in 2017 and invented potent first-in-class TDP-43 inhibitors that can be used for treating neurodegeneration and cystic fibrosis. Dr. Zhang received postdoctoral training in molecular medicine at Cornell University and holds a Ph.D. in genetics from Michigan State University.
Chandler Fang, M.S. Chandler Fang is a financial professional who specializes in investment banking, fund raising and product innovation. Before co-founding Alteron Therapeutic, Chandler worked as the fintech product manager in JP Morgan. He is also intensively involved in the venture capital field in the Silicon Valley and is an adviser of FoundersX Venture.
Biao Ma, Ph.D. Dr. Biao Ma has over ten years of experience in computer-aided drug design, AI modeling and application development. He earned his Ph.D. degree from Gifu University and then worked as a senior researcher at Foundation for Biomedical Research and Innovation at Kobe (FBRI, whose president Tasuku Honjo was awarded the Nobel Prize in Physiology and Medicine 2018) from 2016 to 2021. Dr. Ma is also the research scientist of RIKEN Center for Computational Science, he aims to accelerate drug discovery using HPC (eg. Fugaku) and AI technology. He is also a member of the Life Intelligence Consortium (LINC, which is Industry-Government-Academia Collaboration for the Development of Whole Process Pharmaceutical AI Technology).